| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Sands Capital Life Sciences Pulse Fund II, L.P. is 10% Owner at IKT.
Net of sales, the IKT filings show accumulation of 2,068,965 shares.
Sands Capital Life Sciences Pulse Fund II, L.P. has 1 Form 4 filing on record in November 2025, as 10% Owner at Inhibikase Therapeutics (IKT), 2025.
The 1 reported transaction was 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $3.0M and no sales.
The only open-market purchase was 2,068,965 shares of IKT at an average $1.45 on November 21, 2025, about $3.0M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | IKT Inhibikase Therapeutics, Inc. | 10% Owner | Buy | 2,068,965 | $1.45 | $2,999,999.25 | +18.9% | +16.8% | - |